What is the future of stem cell research? Embryonic cells were once so controversial that President George W. Bush limited federal funding in 2001 (a policy that was overturned by President Obama in 2009). Now there is a new type of stem cell, similar to embryonic stem cells, called induced pluripotent stem cells. We’ve all heard the claims concerning the extraordinary potential of stem cells (be they embryonic or induced) in the treatment of human disease. What will be the first commonly used stem cell therapy?
This past August, the Department of Obstetrics, Gynecology and Reproductive Scienceat the Icahn School of Medicine sent a team of maternal-fetal medicine specialists and gynecologic surgeons to Letsholathebe II Memorial Hospital in Maun, Botswana to establish a new global health site.
Being nominated as part of this team was truly an honor. I’ve been an active member of our department’s Global Women’s Health Program for the past four years, primarily working as an obstetrician in a remote area of Guatemala. However, this was my first experience in actually working to establish a new site.
The opening this year of Mount Sinai Doctors Brooklyn Heights brings coordinated, efficient and quality outpatient medical care to the borough for the very first time. Medical care at this office, located at 300 Cadman Plaza West (One Pierrepoint Plaza) on the 17th and 18th floors, is community-based and convenient. I am the medical director of what our patients have been referring to as “medical services under one roof” or a “medical mall”. I’m also the medical director of WESTMED Practice Partners, a company that builds and manages large centers like this for comprehensive outpatient care.
Ovarian cancer is a heterogeneous and rapidly progressive disease of low prevalence and poor survival. In the United States the number of deaths attributed to ovarian cancer approximates that of all other gynecologic malignancies combined. Unfortunately, the majority (75%) of women diagnosed with ovarian carcinoma continue to have advanced stage disease (Stage III/ IV), with widespread metastases throughout the peritoneal cavity, lymph nodes, liver or lungs. Presently less than 20% of women with ovarian cancers are detected when the cancer is still confined to the ovary (Stage I).
Glioblastoma (GBM) is the most common and most aggressive brain tumor, known to be a highly invasive and rapidly spreading disease. Even with aggressive treatment such as surgery, radiation, and chemotherapy, they are almost always incurable.
The Mount Sinai Comprehensive Brain Tumor Program is pioneering the use of electrical tumor treating fields to be used with conventional therapy. The device, manufactured by Novocure, is called NovoTTF and it is FDA approved for recurrent GBM. It consists of a head cap that produces changes in electrical fields, which is worn continuously.
My name is Bill Weinzimmer and I am an advanced prostate cancer survivor. When I was diagnosed 18 years ago, I was told I only had 18 months to live. Thanks to the amazing care I received from Dr. Simon J. Hall at The Mount Sinai Hospital, and the significant changes I made in my life, I am still alive and active 18 years later at 83-years-young. I hope my experiences and tips will provide inspiration to others diagnosed with cancer, as well as to their families.
To address these challenges, and strengthen the capacity of health professionals and policymakers in Southeast Asia, Mount Sinai physicians under the leadership of Philip J. Landrigan, MD, MSc, the Ethel H. Wise Professor of Community Medicine and Dean for Global Health at The Mount Sinai Medical Center, have established a formal collaboration with the Chulabhorn Research Institute (CRI) in Bangkok, Thailand. Under the auspices of CRI and the World Health Organization (WHO), the physicians are sharing their knowledge and expertise with health care workers in Southeast Asia. Mount Sinai is world renowned for its work in environmental and occupational medicine.
Today’s standard therapies for cancer exist because people have participated in clinical trials – yet choosing to participate in a cancer clinical trial is an important personal decision that can be intimidating for many patients. In order to better help patients understand cancer clinical trials, the reasons to participate in them, and clinical research at Mount Sinai, The Tisch Cancer Institute has released a new video, “Clinical Trials at Mount Sinai: Moving the Field Forward.”